University of Leipzig Heart Center
|
|
- Denis Jordan
- 6 years ago
- Views:
Transcription
1 Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock Holger Thiele, MD Uwe Zeymer, MD; Franz-Josef Neumann, MD; Miroslaw Ferenc, MD; Hans-Georg Olbrich, MD; Jörg Hausleiter, MD; Gert Richardt, MD; Marcus Hennersdorf, MD; Klaus Empen, MD; Georg Fuernau, MD; Steffen Desch, MD; Ingo Eitel, MD; Rainer Hambrecht, MD; Jörg Fuhrmann, MD; Michael Böhm, MD; Henning Ebelt, MD; Steffen Schneider, PhD; Gerhard Schuler, MD; Karl Werdan, MD on behalf of the IABP-SHOCK II Trial Investigators University of Leipzig Heart Center
2 Disclosures Funding: German Research Foundation German Heart Research Foundation German Cardiac Society Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte University of Leipzig Heart Center Unrestricted grant by: Maquet Cardiopulmonary AG, Hirrlingen, Germany Teleflex Medical, Everett, MA, USA Potential Conflict of Interest: Research Funding: Terumo, Lilly, Maquet Cardiovascular, Teleflex Medical Consulting: Maquet Cardiovascular, Lilly Speaker Honoraria: Lilly, Astra Zeneca, Daiichi Sankyo, Boehringer Ingelheim, Maquet Cardiovascular, Medicines Company
3 Background IABP in Cardiogenic Shock History: 1962 Animal studies Moulopoulos et al. Am Heart J 1962;63: First clinical description in shock Kantrowitz et al. JAMA 1968;203: Hemodynamic effects in shock, Mortality unchanged Scheidt et al. NEJM 1973;288: > 40 years > 1 Million patients treated, low complication rate, Benchmark registry Ferguson et al. JACC 2001;38:
4 Background Guidelines Van de Werf et al. Eur Heart J 2008;29: Wijns et al. Eur Heart J 2010;31: Antman et al. Circulation 2004;110: IABP in AMI complicated by cardiogenic shock ESC Class IC ACC/AHA Class IB
5 Background Mortality IABP vs no IABP - Metaanalysis Trial IABP n/n No IABP n/n 30-day mortality Risk difference No reperfusion Moloupoulos 24/34 15/15 Overall 24/34 15/ (-0.47 to -0.12) Thrombolysis Stomel 28/51 10/13 Kovack 10/27 13/19 Bengtson Waksman 48/99 11/20 58/101 17/21 GUSTO-1 SHOCK registry 30/62 220/ / /417 NRMI-2 TT 1068/ /3501 Overall 1415/ / (-0.20 to -0.16) Primary PCI NRMI-2 PCI AMC CS 956/ / /955 26/93 Overall 1049/ / (0.03 to 0.10) Overall 2488/ / (-0.13 to -0.09) IABP No IABP Sjauw et al. Eur Heart J 2009;30:
6 Background IABP Use (%) IABP-Use in Cardiogenic Shock ALKK GUSTO I GUSTO III Euro Heart Survey Worcester-Registry NRMI-2 NRMI 2-4 SHOCK-Registry SHOCK-Trial Thiele et al. Eur Heart J 2010,31:
7 Methods Study Sites and Organisation DSMB: Kurt Huber Ferenc Follath Bernhard Maisch Johannes Haerting Steering committee: Holger Thiele Karl Werdan Uwe Zeymer Gerhard Schuler Support + Patronage:
8 Methods IABP-Shock-II Trial Timelines Year 1 Year 2 Year 3 Year 4 Year Preparation (Study protocol, IRB, etc.) Initiation Patient recruitment Follow-up Database cleaning Statistics Database cleaning Statistics Milestone 1 1. Patient Milestone 2 1. Interimanalysis Milestone 3 2. Interimanalysis Milestone 4 Last patient Milestone 5 Final Analysis Primary Endpoint Milestone 6 Final Analysis Follow-up 1/600 Patients 06/ /600 Patients 03/2012
9 Methods Statistical Methodology Sample Size Estimated 12% absolute difference in survival rates Sequential statistical design with 2 interim analyses (33% and 66% of patients) Significance level at 1st or at 2nd interim analysis. Final analysis at α-level patients To compensate losses in follow-up and putative center effect 600 patients Primary Study Endpoint: 30-day all-cause mortality Secondary Study Endpoints: - Hemodynamic parameters (mean BP, heart rate pre and post revascularization) - Serum-lactate (every 8 h for 48 h) - SAPS-2 Score - Serial creatinine-level and creatinine-clearance (Cockcroft-Gault-formula) - Inflammatory reaction (CRP) Process of care - Time until hemodynamic stabilization - Catecholamine dose and duration - Requirement for LVAD-implantation or HTx - Requirement for renal replacement therapy - Length of ICU-stay - Length of mechanical ventilation - Mortality after 6 and 12 months Thiele et al. Am Heart J 2012;163:938-45
10 Results Trial Flow and Treatment 790 patients with AMI and cardiogenic shock screened 600 randomized 190 excluded because of exclusion criteria - 60 no informed consent - 47 resuscitation >30 minutes - 19 shock duration >12 hours - 18 severe peripheral artery disease - 14 participation in another trial - 13 no intrinsic heart activity - 9 mechanical complication - 3 shock of other cause - 3 comorbidity with life expectancy <6 months - 2 severe cerebral deficit - 2 age >90 years 301 randomized to IABP 288 received IABP 13 did not receive IABP - 10 died before IABP insertion - 3 protocol violation (2 not suitable for revascularization, 1 serious kinking) Allocation 299 randomized to control 269 received control therapy 30 cross-over to IABP (22 first day, 8 day 1-8) - 4 mechanical complications - 25 protocol violation - 1 unknown reason 301 intended early revascularization 287 primary PCI 3 primary CABG 11 no revascularization - 3 not suitable for revascularization - 4 coronary artery disease with no identifiable culprit lesion - 4 no coronary artery disease Revascularization 299 intended early revascularization 288 primary PCI 3 primary CABG 8 no revascularization - 1 not suitable for revascularization - 2 coronary artery disease with no identifiable culprit lesion - 5 no coronary artery disease 300 with 30-day follow-up - 1 lost to follow-up 300 primary endpoint analysis Follow-up Primary endpoint analysis 298 with 30-day follow-up - 1 withdrew informed consent 298 primary endpoint analysis
11 Results Patient Characteristics IABP (n=301) Control (n=299) Age (years); median (IQR) 70 (58-78) 69 (58-76) Male sex; n (%) 202 (67.1) 211 (70.6) Current Smoking; n/total (%) Hypertension; n/total (%) Hypercholesterolemia; n/total (%) Diabetes mellitus; n/total (%) 96/295 (32.5) 213/296 (72.0) 122/295 (41.4) 105/297 (35.4) 108/299 (36.1) 199/299 (66.6) 105/299 (35.1) 90/299 (30.1) Prior myocardial infarction; n/total n (%) 71/300 (23.7) 61/299 (20.4) Fibrinolysis < 24 h before randomization; n/total (%) 28/301 (9.3) 20/299 (6.7) STEMI/LBBB; n/total (%) NSTEMI; n/total (%) 200/300 (66.7) 96/300 (32.0) 212/298 (71.1) 81/298 (27.2) Resuscitation before randomization; n/total (%) 127/301 (42.2%) 143/299 (47.8) Signs of impaired organ perfusion; n/total (%) Altered mental status Cold, clammy skin and extremities Oliguria Serum lactate >2.0 mmol/l 215/300 (71.7) 257/300 (85.7) 90/300 (30.0) 226/300 (75.3) 232/299 (77.6) 245/299 (81.9) 99/299 (33.1) 218/298 (73.2) Creatinine clearance (ml/min); median (IQR) 60.7 ( ) 56.8 ( ) Infarct related artery; n/total (%) LAD LCX RCA Left main Bypass graft 132/293 (45.1) 55/293 (18.8) 73/293 (24.9) 26/293 (8.9) 7/293 (2.4) 121/293 (41.3) 57/293 (19.5) 79/293 (27.0) 28/293 (9.6) 8/293 (2.7) Multivessel disease; n/total (%) 235/296 (79.4) 228/293 (77.9) Left ventricular ejection fraction (%); median (IQR) 35 (25-45) 35 (25-45)
12 Results Treatment + Process of Care Outcomes Variable IABP (n=301) Control (n=299) p Primary PCI; n/total (%) 287/301 (95.3) 288/299 (96.3) 0.55 Stent implanted; n/total (%) 273/301 (90.7) 266/299 (89.0) 0.48 Drug-eluting stent; n/total (%) 126/301 (41.9) 123/299 (41.1) 0.86 Immediate PCI of non-culprit lesions; n/total (%) 90/301 (29.9) 81/299 (27.1) 0.45 Immediate bypass surgery; n/total (%) 8/301 (2.7) 10/299 (3.3) 0.62 Staged bypass surgery; n/total (%) 3/301 (1.0) 4/299 (1.3) 0.72 Active left ventricular assist device; n/total (%) 11/301 (3.7) 22/299 (7.4) Mild hypothermia; n/total (%) 106/301 (35.2) 120/299 (40.1) 0.21 Mechanical ventilation; n/total (%) 240/301 (79.7) 252/299 (84.3) 0.15 Mechanical ventilation duration (days); median (IQR) 3.0 ( ) 3.0 ( ) 0.44 ICU treatment (days); median (IQR) 6.0 ( ) 6.0 ( ) 0.34 Renal replacement therapy; n/total (%) 62/301 (20.6) 47/299 (15.7) 0.12 Catecholamines (μg/kg per minute); median (IQR) Dopamine Norepinephrine Epinephrine Dobutamine 4.1 ( ) 0.3 ( ) 0.3 ( ) 10.2 ( ) 4.2 ( ) 0.4 ( ) 0.3 ( ) 9.0 ( ) Duration of catecholamines (days), median (IQR) 3.0 ( ) 3.0 ( ) 0.81 Time - hemodynamic stabilization (days); median (IQR) 3.0 ( ) 3.0 ( )
13 Results Simplified Acute Physiology Score-II Simplified Acute Physiology Score-II P=0.89 P=0.34 P=0.02 P=0.005 P= IABP Control 0 Baseline Day 1 Day 2 Day 3 Day 4
14 Results Estimated Glomerular Filtration Rate (ml/min) Renal Function (egfr) 100 P=0.12 P=0.55 P=0.96 P=0.55 P= IABP Control Baseline Day 1 Day 2 Day 3 Day 4
15 Results Serum Lactate (mmol/l) Serum Lactate P=0.09 P=0.43 IABP Control P=0.12 P= P=0.32 P=0.32 P= Baseline 8 hours 16 hours 24 hours 32 hours 40 hours 48 hours
16 C-Reactive Protein (mg/l) Results Inflammatory Reaction (CRP) IABP Control P=0.39 P= P= P= P= Baseline Day 1 Day 2 Day 3 Day 4
17 Results Primary Study Endpoint (30-Day Mortality) Mortality (%) Control IABP 41.3% 39.7% P=0.92 by log-rank test Relative risk 0.96; 95% CI ; P=0.69 by Chi 2 -Test Time after Randomization (Days)
18 Results Subgroups (30-Day Mortality) Baseline Variable N 30-Day Mortality (%) IABP Control Relative Risk (95% CI) P-Value for Interaction Female Male ( ) 0.92 ( ) 0.61 Age <50 years Age years Age >75 years ( ) 0.95 ( ) 1.07 ( ) 0.09 Diabetes No diabetes ( ) 0.96 ( ) 0.82 Hypertension No hypertension ( ) 0.67 ( ) 0.05 STEMI/LBBB NSTEMI ( ) 0.98 ( ) 0.76 Anterior STEMI Non-anterior STEMI ( ) 1.16 ( ) 0.14 Previous infarction No previous infarction ( ) 0.86 ( ) 0.04 Hypothermia No hypothermia ( ) 0.89 ( ) 0.31 Blood pressure <80 mmhg Blood pressure 80 mmhg ( ) 0.92 ( ) IABP Control
19 Results Safety IABP (n=300) Control (n=298) P Stroke in-hospital n/total (%) 2/300 (0.7) 5/298 (1.7) 0.28 GUSTO bleeding; n/total n (%) Life-threatening/severe Moderate 10/300 (3.3) 52/300 (17.3) 13/298 (4.4) 49/298 (16.4) Peripheral ischemic complication requiring intervention; n/total n (%) 13/300 (4.3) 10/298 (3.4) 0.53 Sepsis; n/total n (%) 47/300 (15.7) 61/298 (20.5) 0.15
20 Randomized Studies in Cardiogenic Shock Trial Follow-up n/n n/n Revascularization (PCI/CABG) SHOCK SMASH Total 1-year 30 days 76/152 22/32 103/184 83/149 18/23 117/172 Relative Risk 95% CI Relative Risk 95% CI 0.80 (0.66;0.98) 0.87 (0.66;1.29) 0.82 (0.70;0.98) Catecholamines SOAP II (CS Subgroup) Glycoprotein IIb/IIIa-Inhibitors PRAGUE-7 NO Synthase Inhibitors TRIUMPH SHOCK-2 Cotter et al Total IABP IABP-SHOCK I IABP-SHOCK II Total LVAD Thiele et al Burkhoff et al Seyfarth et al Total 28 days 64/145 50/135 Early revascularization Norepinephrine Medical treatment Dopamine (0.55;0.93) In-hospital 15/40 13/ (0.59;2.27) 30 days 30 days 30 days 30 days 30 days 30 days 30 days 30 days 97/201 24/59 4/15 125/275 7/19 119/ /319 9/21 9/19 6/13 24/53 76/180 7/20 10/15 93/215 6/21 123/ /319 IABP 9/20 5/14 6/13 20/47 Up-stream Abciximab NO Synthase inhibition LVAD Standard treatment Placebo Standard treatment IABP 1.14 (0.91;1.45) 1.16 (0.59;2.69) 0.40 (0.13;1.05) 1.05 (0.85;1.29) 1.28 (0.45;3.72) 0.96 (0.79;1.17) 0.98 (0.81;1.18) 0.95 (0.48;1.90) 1.33 ( ) 1.00 ( ) 1.06 ( ) Updated from Thiele et al. Eur Heart J 2010,31:
21 Summary + Conclusions IABP support in cardiogenic shock is safe without significant inherent complications. However, IABP support did not reduce 30-day mortality in this large, randomized, multicenter trial in cardiogenic shock patients complicating myocardial infarction undergoing early revascularization. The primary study endpoint results are supported by a lack of benefit in secondary endpoints.
22 H. Thiele (Chair) G. Schuler K. Werdan U. Zeymer Acknowledgement and Thank You Steering Committee Funding DFG DSHF DGK ALKK University of Leipzig Heart Center Maquet Cardiovascular Teleflex Medical DSMB IABP-SHOCK II Investigators from 37 German Sites J. Haerting (Chair) F. Follath K. Huber B. Maisch Study Sites Leipzig; H. Thiele, G. Schuler, S. Desch, G. Fuernau, I. Eitel, S. de Waha, S. Wetzel, T. Pausewang, A. Leuschner Bad Krozingen: F.-J. Neumann, M. Ferenc Langen. H.-G. Olbrich, H.-B. Hopf Munich German Heart Center: J. Hausleiter, A. de Waha, M. Orban, C. Lennerz, M. Seyfarth Bad Segeberg: G. Richardt, B. Schwarz, M. Abdel-Wahab, R. Toelg, V. Geist, M. Bahnsen-Maaß Heilbronn: M. Hennersdorf, U. Rieman, J. Graf, A. Kuhn, D. Scharpf Greifswald: K. Empen. S. Felix Halle (Saale): K. Werdan, H. Ebelt, A. Schlitt, M. Buerke Bremen: R. Hambrecht, E. Fiehn, A. Fach Ludwigshafen: U..Zeymer, A. K. Gitt, B. Mark, R.Winkler Bad Berka: B. Lauer, J. Fuhrmann Homburg/Saar: M. Böhm, A. Link Jena: H.R. Figulla, M. Ferrari, C. Jung, S. Utschig Lübeck: V. Kurowski, S. Wolfrum, P.W. Radke, H. Schunkert Hennigsdorf: H.-H. Minden Magdeburg: R. C. Braun-Dullaeus, F. Walz, A. Schmeißer Cottbus Heart Center: J. Krülls-Münch, K. Rochor Dresden: R. H. Strasser, G. Simonis Würzburg: S. Maier, G. Ertl Munich Neuperlach: H. Mudra, M. Hug Regensburg: P. Bomba, P. Sick Berlin Banjamin Franklin: C. Tschöpe, H.-P. Schutlheiss Berlin Vivantes am Urban: H. Roth, D. Andresen Cottbus Carl-Thiem-Klinikum: C. Kurek, J. Krülls-Münch Rostock: C. Nienaber, H. Ince, H. Schneider Bad Nauheim: C. Hamm, H. Möllmann Erfurt: H. Lapp Berlin Charité Mitte: G. Baumann, F. Knebel Munich Großhadern: W. Franz Berlin Vivantes AVK: H. Schühlen, L. U. Sttracke Weiden: R. H. Schwinger, H. Bäuml Fulda: V. Schächinger Essen: M. Lichtenberg Unna: D. Gießmann Merseburg: R. Prondzinsky Detmold: U. Tebbe Villingen-Schwenningen: R. Birkemeyer CEC H. Thiele U. Zeymer CRO IHF Ludwigshafen S. Schneider (Statistics chair) T. Oarrak (Statistics) U. Zeymer K. Vonderschmitt Z. Alkisoglu S. Frey B. Messemer
23
University of Leipzig Heart Center
Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock Holger
More informationUniversity of Leipzig Heart Center
Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock Holger
More informationA Future for the IABP in Cardiogenic Shock? Holger Thiele Medical Clinic II (Cardiology/Angiology/Intensive Care) University of Lübeck, Germany
A Future for the in Cardiogenic Shock? Holger Thiele Medical Clinic II (Cardiology/Angiology/Intensive Care) University of Lübeck, Germany Disclosures Funding: German Research Foundation German Heart Research
More informationCULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock. Holger Thiele, MD on behalf of the CULPRIT-SHOCK Investigators
CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock Holger Thiele, MD on behalf of the CULPRIT-SHOCK Investigators Disclosure Statement of Financial Interest Within the past 12 months,
More informationThe Case for Multivessel Revascularization in Shock
The Case for Multivessel Revascularization in Shock Emmanouil S. Brilakis, MD, PhD Minneapolis Heart Institute 9.37 9.49 am Disclosures Consulting/speaker honoraria: Abbott Vascular, American Heart Association
More informationIntracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention
Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention Cardiac Magnetic Resonance Substudy of the AIDA STEMI trial Holger Thiele, MD; Jochen
More informationNew Horizons in Cardiogenic Shock. Timothy D. Henry, MD Director of Cardiology Cedars-Sinai Heart Institute
New Horizons in Cardiogenic Shock Timothy D. Henry, MD Director of Cardiology Cedars-Sinai Heart Institute AMI Shock Mortality Unchanged in > 20 years 74355 US AMI/CGS cases per year 1,2 78954 78500 79823
More informationMild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction the Randomized SHOCK-COOL Trial
Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction the Randomized SHOCK-COOL Trial Georg Fuernau, Johannes Beck, Steffen Desch, Ingo Eitel, Christian Jung, Sandra Erbs, Norman Mangner,
More informationIntraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock
original article Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock Holger Thiele, M.D., Uwe Zeymer, M.D., Franz-Josef Neumann, M.D., Miroslaw Ferenc, M.D., Hans-Georg Olbrich,
More informationIntraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland
More informationSOLVE-TAV. Holger Thiele, MD on behalf of the SOLVE-TAVI Investigators
SOLVE-TAV A 2x2 Randomized Trial of Self-Expandable vs Balloon-Expandable Valves and General vs Local Anesthesia in Patients Undergoing Transcatheter Aortic Valve Implantation Holger Thiele, MD on behalf
More informationIABP SHOCK II trial:
IABP SHOCK II trial: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic
More informationAbciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.
More informationWhy we need a consensus document on cardiogenic shock? ACCA Masterclass 2017
Why we need a consensus document on cardiogenic shock? ACCA Masterclass 2017 Holger Thiele Cardiogenic Shock STEMI Guidelines Steg et al. Eur Heart J.2012;33:2569-2619 Cardiogenic Shock CHF Guidelines
More informationHow to do Primary Angioplasty. - Patients with Cardiogenic Shock
How to do Primary Angioplasty - Patients with Cardiogenic Shock Advanced Cardiovascular Intervention 2011 Dan Blackman Leeds General Infirmary MY CONFLICTS OF INTEREST ARE: Research Grants Medicines Company
More informationAssist Devices in STEMI- Intra-aortic Balloon Pump
Assist Devices in STEMI- Intra-aortic Balloon Pump Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center Athens, Greece Cardiogenic shock 5-10% of pts after a heart attack 60000-70000 pts in Europe/year
More informationCardiogenic shock: Current management
Cardiogenic shock: Current management Janine Pöss Universitätsklinikum des Saarlandes Klinik für Innere Medizin III Kardiologie, Angiologie und internistische Intensivmedizin Homburg/Saar I have nothing
More informationManagement of Cardiogenic shock. Prof. Christian JM Vrints
Management of Cardiogenic shock Prof. Christian JM Vrints none conflicts Management of Cardiogenic Shock Incidence and trends Importance of early revascularization Multivessel disease Left main disease
More informationST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?
ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary Conflicts of interest Advisory Boards Cordis Boston Scientific
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute
More informationRandomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction
Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationA.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
More informationMechanical circulatory support in cardiogenic shock
European Heart Journal (2014) 35, 156 167 doi:10.1093/eurheartj/eht248 REVIEW Novel devices Mechanical circulatory support in cardiogenic shock Karl Werdan 1 *, Stephan Gielen 1, Henning Ebelt 1, and Judith
More informationPrognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction
Prognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction Holger Thiele, MD; Konrad Kubusch, BSc; Steffen Desch,
More informationCounterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece
John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87
More informationCardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands
Cardiogenic Shock Dr. JPS Henriques Academic Medical Center University of Amsterdam The Netherlands Conflict of interest disclosure Research grant Abbott Vascular Research grant Abiomed Inc. Global Impella
More informationHemodynamic improvement upon levosimendan treatment in low cardiac output patients following coronary artery bypass graft
Hemodynamic improvement upon levosimendan treatment in low cardiac output patients following coronary artery bypass graft M. Buerke, K. Krohe, M. Russ, C. Schneider, H. Lemm, R. Prondzinsky, I. Friedrich,
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Multivessel disease and cardiogenic shock: CABG is the optimal revascularization therapy. Contra Prof. Christian JM Vrints Cardiogenic Shock Spiral Acute Myocardial
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationΟξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση. Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας
Οξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας ACUTE HEART FAILURE AND CAD: ACS / LV ischaemic dysfunction Mechanical complications
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationPPCI in STEMI. ESC at the 22nd Annual Conference of the Saudi Heart Association February 21th, 2011
PPCI in STEMI Dr Hassan Mhish Interventional Cardiology Consultant Cardiology Fellowship Program Director Prince Salman Heart Center King Fahd Medical City Riyadh, KSA ESC at the 22nd Annual Conference
More information4/22/2016 Updated. AllinaHealthSystem. Cardiogenic Shock: Definition. No Disclosures. Cardiogenic Shock: Declining (But Still High) Case Fatality Rate
4/22/216 Updated Definition End-organ hypoperfusion secondary to cardiac failure Advanced Cardiopulmonary Support for the Critically Ill Adult April 22, 216 Cardiogenic Shock Michael A. Samara, MD FACC
More informationT he prevalence of significant involvement of the left main
INTERVENTIONAL CARDIOLOGY Sirolimus-eluting stent treatment for unprotected versus protected left main coronary artery disease in widespread clinical routine: 6-month and 3-year clinical follow-up results
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationMANAGEMENT OF CARDIOGENIC SHOCK
MANAGEMENT OF CARDIOGENIC SHOCK CASE PRESENTATION 37 year old Dutch female No known coronary artery disease risk factors 1 week post partum at time of presentation (G3P3) after an uncomplicated normal
More informationAlex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
More informationTicagrelor vs Aspirin in Patients undergoing Coronary- Artery Bypass Grafting
The TiCAB Trial Ticagrelor vs Aspirin in Patients undergoing Coronary- Artery Bypass Grafting Heribert Schunkert, MD on behalf of the TiCAB Investigators TiCAB an investigator initiated trial Sponsor Deutsches
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationOne-Year Outcomes after PCI Strategies in Cardiogenic Shock
Original Article One-Year Outcomes after PCI Strategies in Cardiogenic Shock H. Thiele, I. Akin, M. Sandri, S. de Waha Thiele, R. Meyer Saraei, G. Fuernau, I. Eitel, P. Nordbeck, T. Geisler, U. Landmesser,
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationPercutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.
UvA-DARE (Digital Academic Repository) Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E. Link to publication Citation for published version
More informationC. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
More informationPost resuscitation care and role of urgent angiography after cardiac arrest. Georg Fuernau Luebeck
Post resuscitation care and role of urgent angiography after cardiac arrest Georg Fuernau Luebeck The journey CPR and guidelines European Resuscitation Council American Heart Association International
More informationThe Strategic Reperfusion Early After STEMI study Implications for clinical practice
The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional
More informationSTEMI and Cardiogenic Shock. The rules and solution. Dave Kettles St Dominics and Frere Hospitals East London ZA
STEMI and Cardiogenic Shock. The rules and solution Dave Kettles St Dominics and Frere Hospitals East London ZA Definitions: Shock is a life threatening, but initially reversible state of cellular and
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationEXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) Disclosures Investigator Initiated Trial: NCT00828087. Unrestricted grant from Abbott to the Spanish Heart Foundation.
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationRationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
More informationImpact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,
More informationSTEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia.
STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia. PART 1 Systems of care for STEMI. STEMI Management Coronary angiogram +/- stenting. Prehospital thrombolysis
More informationSTEMI Linee guida ESC Maddalena Lettino, Italy
STEMI Linee guida ESC 2017 Maddalena Lettino, Italy Disclosure Speaker fee: Aspen, Astra Zeneca, BMS, Boehringer, Eli Lilly, DaichiiSankio, Bayer, Pfizer, Sanofi Advisory board member: Astra Zeneca, Eli
More informationPrimary Percutaneous Coronary Intervention
The big 5 in PCI Primary Percutaneous Coronary Intervention W. Wijns (Aalst, BE) Disclosures Consulting Fees: on my behalf go to the Cardiovascular Research Center Aalst Contracted Research between the
More informationRandomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
More informationManagement of ST-elevation myocardial infarction Update 2009 Late comers: which options?
European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationDepartment of Medicine III, Martin Luther-University Halle, Germany b. Unità Operativa di Cardiologia, Ospedale Maggiore, Bologna, Italy c
Comparison of CHADS 2 -Score with CHA 2 DS 2 VASc-Score in a prospective multicenter registry on patients with atrial fibrillation undergoing coronary artery stenting -First results from the AFCAS-trial-
More informationControversies in Cardiogenic Shock. Timothy D. Henry, MD Cedars-Sinai Heart Institute
Controversies in Cardiogenic Shock Timothy D. Henry, MD Cedars-Sinai Heart Institute Key Issues Cardiac Arrest-Cardiogenic shock interaction New SCAI Classification Refractory Shock Shock with Multivessel
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationIntroduction to Acute Mechanical Circulatory Support
Introduction to Acute Mechanical Circulatory Support Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive
More informationSTEMI ST Elevation Myocardial Infarction
STEMI ST Elevation Myocardial Infarction Breakout Session One Moderators: Quinn Capers IV, MD and Scott M. Lilly, MD, PhD Cases Presented by: Umair S. Ahmad, MD 1 Outline 1. Multivessel Revascularization
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationThrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia (TASTE trial)
UCR Uppsala Clinical Research Center Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia (TASTE trial) Main results at 30 days Ole Fröbert, MD, PhD - on behalf of the TASTE investigators
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationFuernau et al. Critical Care (2014) 18:713 DOI /s
Fuernau et al. Critical Care (2014) 18:713 DOI 10.1186/s13054-014-0713-8 RESEARCH Open Access Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationEmergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
More informationBridging With Percutaneous Devices: Tandem Heart and Impella
Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE
More informationPHARMACOLOGICAL MANAGEMENT OF CARDIOGENIC SHOCK
PHARMACOLOGICAL MANAGEMENT OF CARDIOGENIC SHOCK Doron Zahger, MD Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva,
More informationGerman Aortic Valve RegistrY
German Aortic Valve RegistrY C. W. Hamm, F.W. Mohr, H. Möllmann, D. Holzhey, A. Beckmann, H.-R. Figulla, J. Cremer, K.-H. Kuck, R. Lange, R. Zahn, S. Sack, G. Schuler, T. Walther, F. Beyersdorf, M. Böhm,
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationSafety-outcomes of bioresorbable Everolimus eluting scaffold in (German-Austrian-ABSORB RegIsteR)
Safety-outcomes of bioresorbable Everolimus eluting scaffold in 2168 patients with CAD: 30 days follow-up from the GABI-R (German-Austrian-ABSORB RegIsteR) C. Hamm, University of Giessen, Germany on behalf
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationFFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators
FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationBivalirudin Clinical Trials Update Evidence and Future Perspectives
Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS
More informationReperfusion Strategy in Europe: Temporal Trends in Performance Measures for Reperfusion Therapy in ST Elevation Myocardial Infarction
Reperfusion Strategy in Europe: Temporal Trends in Performance Measures for Reperfusion Therapy in ST Elevation Myocardial Infarction F. Schiele 1, M. Hochadel 2, M. Tubaro 3, N. Meneveau 1, W. Wojakowski
More informationPROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study
ESC, Hotline III, Paris, August, 30, 2011 PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study M. Valgimigli, MD, PhD University of Ferrara, ITALY On behalf of the
More informationPercutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.
UvA-DARE (Digital Academic Repository) Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E. Link to publication Citation for published version
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of
More informationDeutsches Aortenklappenregister German Aortic Valve RegistrY
Deutsches Aortenklappenregister German Aortic Valve RegistrY C. W. Hamm, F.W. Mohr, H. Möllmann, D. Holzhey, A. Beckmann, H.-R. Figulla, J. Cremer, K.-H. Kuck, R. Lange, R. Zahn, S. Sack, G. Schuler, T.
More informationWhat is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN
What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN October 2011 Part 2 Summary of newer antithrombotic and antiplatelet agents in STEMI Role of thrombectomy in PPCI
More informationTwo year results of COMPARE-ACUTE Randomised trial of FFR-guided complete revascularization versus infarct artery only treatment in
Two year results of COMPARE-ACUTE Randomised trial of FFR-guided complete revascularization versus infarct artery only treatment in multivessel STEMI patients On behalf of all COMPARE-ACUTE investigators
More informationPCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock
Original Article PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock H. Thiele, I. Akin, M. Sandri, G. Fuernau, S. de Waha, R. Meyer Saraei, P. Nordbeck, T. Geisler, U. Landmesser,
More informationHow to manage ACS patients with Comorbidities? Patients with Renal Failure
How to manage ACS patients with Comorbidities? Patients with Renal Failure François Schiele, MD, PhD Department of Cardiology, University Hospital Jean Minjoz, Besançon, France. Potential conflicts of
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More information